Ascendis Pharma A (ASND) Total Debt (2021 - 2026)
Ascendis Pharma A (ASND) posted Total Debt of $864.8 million for Q1 2026, down 30.63% sequentially from $1.2 billion in Q4 2025, and down 16.23% YoY from $1.0 billion in Q1 2025.
Ascendis Pharma A (ASND) Total Debt (2021 - 2026) Analysis & Trends
Ascendis Pharma A has reported Total Debt for 6 years, with the latest figure at $864.8 million in Q1 2026.
- Quarterly Total Debt fell 16.23% year-over-year to $864.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $864.8 million (down 16.23% YoY) and the FY2025 annual result came in at $1.2 billion, up 41.69% from the prior year.
- Total Debt declined to $864.8 million in Q1 2026 per ASND's latest filing, from $1.2 billion in the prior quarter.
- Over five years, Total Debt peaked at $1.2 billion in Q4 2025 and troughed at $407.3 million in Q4 2022.
- A 5-year average of $793.2 million and a median of $864.8 million in 2026 frame the typical range for Total Debt.
- The sharpest annual moves came in 2022 and 2026: Total Debt jumped 239.19% in 2022, then declined 16.23% in 2026.
- Over 5 years, Total Debt stood at $407.3 million in 2022, then soared by 66.46% to $677.9 million in 2023, then gained by 29.77% to $879.8 million in 2024, then surged by 41.69% to $1.2 billion in 2025, then slumped by 30.63% to $864.8 million in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $864.8 million, $1.2 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 864.78 Mn |
| Dec 31, 2025 | 1.25 Bn |
| Sep 30, 2025 | 1.16 Bn |
| Jun 30, 2025 | 1.06 Bn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | 879.76 Mn |
| Sep 30, 2024 | 1.02 Bn |
| Jun 30, 2024 | 872.60 Mn |
| Mar 31, 2024 | 925.47 Mn |
| Dec 31, 2023 | 677.94 Mn |
| Sep 30, 2023 | 611.03 Mn |
| Jun 30, 2023 | 550.93 Mn |
| Mar 31, 2023 | 542.45 Mn |
| Dec 31, 2022 | 407.27 Mn |
| Sep 30, 2022 | 557.82 Mn |
| Jun 30, 2022 | 546.56 Mn |
| Mar 31, 2022 | 531.61 Mn |
| Dec 31, 2021 | 120.07 Mn |